*
*
*
*Victoria Institute of
*Strategic Economic Studies
*
 
*
*
 
 
*  Home  *  Research Programs  *  Events  *  Staff  *  Students  *  Publications  *  Contact  *
*
*
*
 
  *  
 

Dr Kim Sweeny
Principal Research Fellow
Phone number:
(03) 9919 1349
Email address:
kim.sweeny@vu.edu.au

Qualifications
BEcon (Hons), Sydney; PhD (Econ) Victoria Univ.

Professional experience
Dr. Kim Sweeny is Principal Research Fellow at VISES, specialising in the strategic analysis, assessment and development of new technology and innovation. Mr Sweeny is heavily involved in the Institute’s Pharmaceutical Industry Project, being responsible in particular for the analysis of Australian and international pharmaceutical markets. He has produced reports on, among other topics, the operations of the PBS and pricing and usage outcomes, comparisons of Australian and international pharmaceutical usage and pricing, and the Australian pharmaceutical supply chain. He has presented his findings at various national and international fora. In addition he has undertaken consultancy studies of various aspects of the PBS for pharmaceutical industry clients. He was a lead author on the report on Small Scale Technologies for the Victorian Government and the report on Economic Benefits of the Research Program of the Proposed CRC for Interconnected Knowledge Communities (CRCIKC).

From 1993-2000 Dr. Sweeny was General Manager, Service Industries of the Strategic Industry Research Foundation Ltd (SIRF), a company established by the Victoria Government to develop and manage technology related products. He won, managed and delivered numerous consultancy projects including 3 benchmarking studies, covering biotechnology, pharmaceuticals, diagnostics, medical equipment and clinical trials, for Invest Australia (an arm of the Australian Government) in 1995, 1997, and 2000.

In 1995 and 2000 he undertook studies for Invest Australia on criteria used by multinational companies in deciding where to locate new R&D investments. Around 30 multinational companies were interviewed and asked to rank the importance of 22 selection criteria, such as costs, availability of skilled personnel, scientific research base, proximity to markets/customers, quality of life, cost of living, taxation regimes, economic and political stability etc.

In 1996 he carried out a study of the benefits of pharmaceutical company R&D for the Australian Pharmaceutical Manufacturers Association. This study demonstrated substantial returns from pharmaceutical R&D and included interviews with 25 pharmaceutical companies.

While at SIRF he was instrumental in establishing the Cooperative Research Centre for Microtechnology – a new technology alliance of research organisations, companies and State and Commonwealth Governments undertaking research in micro and nanotechnologies. Industries covered by the CRC include defence, communications, automotive, biotechnology and sport. In 2001 he carried out an assessment of the business case for a new microelectronics design business for the CRC.

Publications

Journal articles

Stenberg, K., Axelson, H., Sheehan, P., Anderson, I., Gülmezoglu, A.M., Temmerman, M., Mason, E., Friedman, H.S., Bhutta, Z.A., Lawn, J.E., Sweeny, K., Tulloch, J., Hansen, P., Chopra, M., Gupta, A., Vogel, J.P., Ostergren, M., Rasmussen, B., Levin, C., Boyle, C., Kuruvilla, S., Koblinsky, M., Walker, N., de Francisco, A., Novcic, N., Presern, C., Jamison, D. and Bustreo, F. on behalf of the Study Group for the Global Investment Framework for Women’s Children’s Health 2013, ‘Advancing social and economic development by investing in women's and children's health: A new global investment framework’, The Lancet, vol. 383, no. 9925, pp. 1333-1354, doi:10.1016/S0140-6736(13)62231-X.

Sweeny, K. 2009, ‘The impact of copayments and safety nets on PBS expenditure’, Australian Health Review, vol. 33, no. 2, pp. 215-230.

Book chapters

Stenberg, K., Sheehan, P., Axelson, H. and Sweeny, K. forthcoming, ‘Investing in the continuum of care for RMNCH’, Chapter 15, Volume 2, , in D. Jamison, S. Horton, H. Gelband, P. Jha, R. Laxminarayan, R. Nugent (eds), Disease Control Priorities in Developing Countries (DCP3), 3rd edn, Volume 2, The Continuum of Reproductive, Maternal, Newborn and Child Health, chap. 15.

Sweeny, K. 2010, ‘Smart technology for healthy longevity: Economic analysis’, Report prepared for ATSE, in G. Tegart, Smart Technology for Health Longevity, Australian Academy of Technological Sciences and Engineering, Melbourne, pp. 65-78.

Sweeny, K. 2006, ‘Australian pharmaceutical pricing in a global context: Trends and issues’, in B. Grewal and M. Kumnick (eds), Engaging the New World: Responses to the Knowledge Economy, Melbourne University Press, Melbourne.

Research reports

Rasmussen, B., English, A., Houghton, J., Lang, J., Maharaj, N., Sweeny, K. and Rasmussen, A. 2012, Chinese Export Opportunities for Victorian Companies, Report to Department of Business Innovation and Innovation (Victoria), Melbourne, February.

Sweeny, K. 2011, The Impact of PBS Reforms on PBS Expenditure and Savings: Revised Estimates 2005-06 To 2017-18, Report To Pfizer Australia, January.

Sweeny, K., English, A., Zhuang, X, and Jiang, K., 2011, Technology and Policy Roadmap for Electric Vehicles in China, Report to Australian Department of Climate Change and Energy Efficiency, CSES, Melbourne, October.

English, A., Sweeny, K., Zhuang, X., Jiang, K. and Sheehan, P. 2011, Pathways to a Low Carbon Economy in China, Report to Australian Department of Climate Change and Energy Efficiency, CSES, Melbourne, October.

Sheehan, P. and Sweeny, K. 2010, Industry Policy in the Transition to a Low Carbon Economy, Report prepared for Department of Innovation, Industry and Regional Development, Melbourne, July.

Sheehan, P., English, A., Grewal, B., Sweeny, K., Nielson, J., Sun, F. and Cheng, E. 2010, The Transition to a Low Carbon Economy: Implementation Issues and Constraints within China's Changing Economic Structure, Final Report to Department of Climate Change (Canberra), June, CSES, Melbourne.

Sweeny, K. and English, A. 2010, Identifying Policies and Implementation Strategies for Improving Energy Efficiency: Case Study 1: High Fuel Efficiency Motor Vehicles, Final Report to Department of Climate Change, June.

Sweeny, K. and Grubert, N. 2010, Pharmaceutical Pricing and Reimbursement in Australia, Decision Resources, Burlington, October.

Sweeny, K. and Rasmussen B. 2010, CDM-Net Project Final Report, Section 7, Precedence Healthcare, Melbourne, January.

Sweeny, K. 2010, Smart Technology for Healthy Longevity: Economic Analysis, Report prepared for Australian Academy of Technological Sciences and Engineering, Melbourne, January, in G. Tegart (ed.), Smart Technology for Health Longevity, Australian Academy of Technological Sciences and Engineering, Melbourne, pp. 65-78.


Rasmussen, B., Sweeny, K. and Maharaj, N. 2009, Health Cluster, Making VU Cluster Coordination Committee Input Report, CSES, April.

Sweeny, K. and Sheehan, P. 2009, The Impact of PBS Reforms on PBS Expenditure and Savings: Actual and Projected from 2008-09 to 2017-18, Report to Medicines Australia, Centre for Strategic Economic Studies, Victoria University, Melbourne.

Sweeny, K. and Rasmussen, B. 2009, An Economic Analysis of Expected Benefits from the CRC Bid’s Research Program, CSES, January.

Sheehan, P., Rasmussen, B., Sweeny, K., Grewal, B., Ahmed, A. and Maharaj, N. 2008, Investing in the Future: An Assessment of the Returns to Investment in Health Innovation, Framework Paper prepared for the Life Science and Innovation Forum (LSIF) VI, Lima, Peru, 14-15 August.

Sheehan, P. and Sweeny, K. 2007, The Value of Medicines in Australia, Report to Medicines Australia, CSES, Victoria University, Melbourne.

Sheehan, P., Rasmussen, B. and Sweeny, K. 2007, ‘Developing an Integrated Approach to Emerging Health Challenges’, Framework Paper prepared for the APEC Life Science Innovation Forum V, Adelaide, 19-20 April.

Sweeny, K. 2006, Modelling the Impact of Proposed PBS Policy Changes, report to Medicines Australia, April, CSES, Victoria University, Melbourne.

Sweeny, K. 2006, A Comparison of the PBS Prices of Popular Patent-Protected and Off-Patent Medicines with Prices in the United Kingdom, report to Pfizer Australia, March, CSES, Victoria University, Melbourne.

Sweeny, K. 2006, The Market for Antidepressants in Australia, report to Pfizer Australia, February, CSES, Victoria University, Melbourne.

Sweeny, K. 2006, New Drugs, Generics and Pricing Options: An Analytical Framework for the Assessment of Alternative Policies Phase One: New Drugs for the PBS, report to Pfizer Australia, February, CSES, Victoria University, Melbourne.

Sheehan, P., Rasmussen, B. and Sweeny, K. 2006, ‘Sustainable Health Care Systems to Support Innovation’, Framework Paper prepared for the Fourth Annual APEC Life Science Innovation Forum (LISF), Hoi An, Vietnam, 6-7 September.

Sweeny, K. 2005, Policies for Pricing Innovative and Off-Patent Medicines: A Comparison of Current Government Policy with a Two Market Policy, report to Medicines Australia, December, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Options for Restructuring the Pharmaceutical Benefits Scheme Phase Two: Drug Prices in Australia: A Comparative Review and Analysis of Changes, report to Medicines Australia, August, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Options for Restructuring the Pharmaceutical Benefits Scheme Phase One: The Australian Pharmaceutical Market in Context, report to Medicines Australia, August, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, New Listing and Pricing Arrangements for Generic Medicines: An Assessment, report to Pfizer Australia, July, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Proposed New Listing and Pricing Arrangements for Generic Medicines: An Assessment, with P. Sheehan, report to Medicines Australia, March, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Generic Drugs, Savings and Medicine Policy Phase Two: New Drugs, Future PBS Costs and Alternative Approached to Pricing Policy for New Drugs, report to Medicines Australia, January, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Generic Drugs, Savings and Medicine Policy Phase One: Historical Analysis of Generic Markets and Assessment of the Future Impact of Generics - Impact of Price Reductions Following Patent Expiry, report to Medicines Australia, January, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, Generic Drugs, Savings and Medicine Policy Phase One: Historical Analysis of Generic Markets and Assessment of the Future Impact of Generics, report to Medicines Australia, January, CSES, Victoria University, Melbourne.

Sweeny, K. 2004, Savings in the Cost of the PBS from Reducing the Price of Off-Patent Drugs, report to Bristol-Myers Squibb Australia, CSES, Victoria University, Melbourne.

Sweeny, K. and Houghton, J. 2004, The Economic Benefits of the Research Program of the Proposed CRCIKC, report to CRC for Enterprise Distributed Systems Technology, CSES, Victoria University, Melbourne.

Sweeny, K. 2004, The Health Technologies Institute: An Initial Economic and Financial Assessment, report to Department of Innovation, Industry and Regional Development, CSES, Victoria University, Melbourne.

Sweeny, K. 2003, The Value of Medicines and Australian Pharmaceutical Pricing Policy, A Case Study of AIIRAs, report to Bristol-Myers Squibb Australia, CSES, Victoria University, Melbourne.

Sheehan, P., Sweeny, K., Rasmussen, B., Tegart, G. and Nicolau, D. 2003, Small Scale Technologies: Directions for Victoria, report to the Victorian Department of Innovation, Industry and Regional Development, Melbourne, September.


Conference presentations

Sweeny, K. 2009, ‘The Benefits and Cost of Regulation and Health Outcomes’, presentation at the Pharmaceutical Regulations Forum, Sydney, 18 June.

Sweeny, K. 2009, ‘Reforms to the PBS and Long Term Sustainability’, presentation at the 5th Annual Future of the PBS Conference, Sydney, 1 May.

Sweeny, K. 2009, ‘The Sustainability of the PBS’, presentation at the 10th Annual Health Congress, Sydney, 25 March.

Sweeny, K. 2008, ‘The Sustainability of the PBS’, invited presentation to the 11th Annual Health Congress, Sydney, 24 March.

Sheehan, P. and Sweeny, K. 2008, ‘The Evolution of the PBS: An Assessment of the Recent Reforms’, invited presentation at the 4th Annual Future of the PBS Conference, Sydney, 6-7 May.

Sheehan, P., Rasmussen, B. and Sweeny, K. 2006, ‘Sustainable Health Care Systems to Support Innovation’, invited framework paper presented at the Fourth Annual APEC Life Science Innovation Forum (LISF), Hoi An, Vietnam, 6-7 September.
Sweeny, K. 2005, ‘The Future of the PBS’, invited paper presented at the 3rd Annual Pharma Marketing Congress 2005, Sydney, 18 May.

Sweeny, K. 2004, FTA Discussion Open Forum, panel participant, presentation at the 2nd Annual Future of Pharmaceutical Benefits Scheme, Sydney, 24–25 August.

Sweeny, K. 2004, ‘Australian Pharmaceutical Pricing in a Global Context: Trends and Issues, paper presented at the Merck Company Foundation Program on Pharmaceutical Policy Issues, Policy Conference 2004, Lafayette Hill, Pennsylvania, 1–2 March.

Sweeny, K. 2004, invited workshop participant at Better Health Care Through Electronic Information, Global Access Partners (GAP) Forum. Sydney, 15 September.

Sweeny, K. 2003, ‘Implications of recent trends in pricing and usage under the PBS’, paper presented at the conference ‘The Future of the Pharmaceutical Benefits Scheme: Sustaining and Improving Australians’ Access to Quality Medicines’, PBS, Sydney, 11-12 September.

Working papers

Sweeny, K. 2007, ‘Trends and Outcomes in the Australian Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 36, December, CSES, Victoria University, Melbourne.

Sweeny, K. 2007, ‘Key Aspects of the Australian Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 35, November, CSES, Victoria University, Melbourne.

Sweeny, K. 2007, ‘The Pharmaceutical Industry in Australia’, Pharmaceutical Industry Project Working Paper No. 34, September, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, ‘Drug Prices in Australia: An International Comparison’, Pharmaceutical Industry Project Working Paper No. 29, September, CSES, Victoria University, Melbourne.

Sweeny, K. 2005, ‘Accounting for Growth in the Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 28, September, CSES, Victoria University, Melbourne.

Sweeny, K. 2004, ‘Review of Findings: Australian Pharmaceutical Pricing in a Global Context’, Pharmaceutical Industry Project Working Paper No. 19, April, CSES, Victoria University, Melbourne.

Sweeny, K. 2004, ‘Australian Pharmaceutical Pricing in a Global Context: Trends and Issues’, Pharmaceutical Industry Project Working Paper No. 16, February, CSES, Victoria University, Melbourne.

Sweeny, K. 2003, ‘Price and Quantity Trends in the Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 14, August, CSES, Victoria University, Melbourne.

Sheehan, P. and Sweeny, K. 2002, ‘Competition and Drug Pricing in the PBS: An Economic Interpretation’, Pharmaceutical Industry Project Working Paper No. 12, August, CSES, Victoria University, Melbourne.

Sweeny, K. 2002, Demand and Price Dynamics in the International Market’, Pharmaceutical Industry Working Paper No. 11, August, CSES, Victoria University, Melbourne.

Rasmussen, B. and Sweeny, K. 2002, ‘Development Paths for Australian Biomedical Firms’, Pharmaceutical Industry Project Working Paper No. 8, September, CSES, Victoria University, Melbourne.

Sweeny, K. 2002, ‘Demand and Price Dynamics within the Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 6, June, CSES, Victoria University, Melbourne.

Sweeny, K. 2002, ‘Trends in the Use and Cost of Pharmaceuticals Under the Pharmaceutical Benefits Scheme’, Pharmaceutical Industry Project Working Paper No. 5, June, CSES, Victoria University, Melbourne.

Sweeny, K. 2002, ‘Technology Trends in Drug Discovery and Development: Implications for the Development of the Pharmaceutical Industry in Australia’, Pharmaceutical Industry Project Working Paper No. 3, March, CSES, Victoria University, Melbourne.